B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lymphoma study pulled before it began: N-803 after CAR t never tested
Disease control TerminatedThis study aimed to see if the drug N-803 is safe to give as maintenance therapy after CAR T-cell treatment for people with relapsed or refractory B-cell non-Hodgkin lymphoma. It was designed for adults who had already responded to CAR T therapy. However, the trial was withdrawn …
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New combo therapy aims to tackle tough lymphoma
Disease control OngoingThis study tests a new treatment for people with relapsed or hard-to-treat B-cell Non-Hodgkin lymphoma. It combines two immune-based therapies: a bispecific antibody and CAR-T cells. The goal is to see if the combination is safe and helps control the cancer. About 48 adults will …
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
Can a simple drug stop CAR-T's dangerous side effects?
Disease control OngoingThis study tests whether the drug anakinra can prevent or reduce severe side effects like brain problems and cytokine release syndrome caused by CAR-T cell therapy. About 62 adults with certain blood cancers (B-cell ALL, lymphoma) will receive anakinra alongside their CAR-T treat…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug combo aims to stop cancer return after transplant
Disease control OngoingThis study tests a drug called blinatumomab given after a stem cell transplant to help prevent relapse in people with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma. About 44 participants will receive the drug as maintenance therapy. The goal is to see if it i…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New combo therapy shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests whether adding the drug acalabrutinib to CAR T-cell therapy (a treatment that uses a patient's own immune cells to fight cancer) is safe and effective for adults with certain types of B-cell lymphoma. About 23 participants will receive the combination. The goal i…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New drug combo aims to prevent lymphoma relapse after transplant
Disease control OngoingThis study tests whether combining two drugs, pembrolizumab and tazemetostat, can help prevent aggressive B-cell non-Hodgkin lymphoma from returning after stem cell transplant or CAR T-cell therapy. About 32 adults who have already had or are about to have one of these treatments…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 02, 2026 11:51 UTC
-
Blood test may replace CT scans for lymphoma patients
Knowledge-focused OngoingThis study looks at whether a blood test can spot signs of lymphoma coming back after chemotherapy, possibly earlier than regular CT scans. About 500 adults with aggressive B-cell Non-Hodgkin lymphoma will give blood samples after treatment. The goal is to see if this test could …
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 17, 2026 02:15 UTC
-
Blood test may predict lymphoma prognosis without scans
Knowledge-focused OngoingThis study looks at whether measuring tumor DNA in the blood (ctDNA) can help predict how B-cell non-Hodgkin lymphoma will progress. Researchers will collect blood samples from 60 patients before and during treatment. The goal is to see if changes in ctDNA levels match with stand…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 11, 2026 12:09 UTC